Estimation of the direct health and indirect societal costs of diabetes in the UK using a cost of illness model
Authors' conclusion
Diabetes remains a considerable cost burden in the UK, and the majority of those costs are still spent on potentially preventable complications. Although rates of some complications are reducing, prevalence continues to increase and effective approaches to primary and secondary prevention continue to be needed. Improvements in data capture, data quality and reporting, and further research on the human and financial implications of increasing incidence of Type 2 diabetes in younger people are recommended.
Study context
- Population
- People with T1D, T2D and GDM in the UK nations; excess costs vs general UK population
- Outcome
- Direct health costs and indirect societal costs (productivity losses due to absenteeism and premature mortality) of diabetes
- Follow-up
- 2021/22
Methodological detailspopulation-based cost of illness model, pragmatic review of data sources
- Population-based cost of illness model
- Pragmatic review of data sources
Main finding
As reported in the abstract
Direct costs of diabetes
£10.7 billion
Share of direct costs related to diagnosis and treatment (rest: excess costs of complications)
just over 40%
Indirect costs
£3.3 billion
Observational data: associations, not effects.
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →